Reduced kidney function decline with semaglutide across kidney risk categories: analyses from the FLOW trial
Authors:
David Cherney1; Nicolas Belmar2; Trine Welløv Boesgaard2; Julie Funch Furberg2; Thomas Idorn2; Kenneth W. Mahaffey3; Johannes F. E. Mann4,5; Vlado Perkovic6; Richard E. Pratley7; Katherine R. Tuttle8,9; Peter Rossing10